Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06655428 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The REDUCE EU Study - Endobronchial Thermal Liquid Ablation (ETLA) for the Treatment of Emphysema

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 28, 2025 (before its estimated February 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Nov 2024 to Jan 10, 2025
    • Site details revised at 7 of 7 sites
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Morair Medtech, LLC
1 trial monitored
See all monitored trials
COPD
1,119 trials monitored
See 34 trials at risk
The goal of this clinical trial is to learn if bronchoscopic lung volume reduction with endobronchial thermal liquid ablation (ETLA) works to treat severe emphysema in terms of feasibility and safety. Participants will: * Have up to two ETLA procedures * Complete five clinic follow-up visits and two virtual follow-up visits.
Trial Details
NCT Number NCT06655428
Lead Sponsor Morair Medtech, LLC
Conditions
(from sponsor)		 Emphysema or COPD, Emphysema, Emphysema, Pulmonary, COPD, COPD (Chronic Obstructive Pulmonary Disease)
Related terms Emphysema, Lung Diseases, Obstructive, Pulmonary Disease, Chronic Obstructive, Pulmonary Emphysema, Respiratory Tract Diseases
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov